Financial giants have made a conspicuous bearish move on Alnylam Pharmaceuticals. Our analysis of options history for Alnylam Pharmaceuticals ALNY revealed 11 unusual trades. Delving into the ...

Alnylam has said it will not proceed with a clinical trial of its RNAi drug vutrisiran in the rare eye disorder Stargardt disease – at least for now – tying its decision to President Joe Biden ...

Alnylam is suspending further development of a clinical-stage RNAi therapeutic designed to treat Type 2 diabetes among participants with obesity. The discontinuation is part of portfolio ...

--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the presentation of new results from its Phase 1 study of nucresiran ...